Psychosocial health and levels of employment in 851 hypopituitary Swedish patients on long-term GH therapy

Psychoneuroendocrinology

Volumn 38, Issue 6, 2013, Pages 842-852

  Holmer, Helene ^a,b   Svensson, Johan ^c   Rylander, Lars ^d   Johannsson, Gudmundur ^c   Rosén, Thord ^c   Bengtsson, Bengt åke ^c   Thorén, Marja ^e   Höybye, Charlotte ^e   Degerblad, Marie ^e   Bramnert, Margareta ^b   Hägg, Erik ^f   Engström, Britt Edén ^g   Ekman, Bertil ^h   Erfurth, Eva Marie ^b  

^a CENTRAL HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^h LINKÖPING UNIVERSITY   (Sweden)

Author keywords

GH deficiency; GH therapy; Hypopituitarism; Long term hormone replacement; Psychosocial health employment

Indexed keywords

ANALGESIC AGENT; ANTIDEPRESSANT AGENT; GROWTH HORMONE;

ADULT; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ARTICLE; CONTROLLED STUDY; CRANIOPHARYNGIOMA; DISABILITY; DISEASE DURATION; DRUG USE; EDUCATIONAL STATUS; EMPLOYMENT; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPOPITUITARISM; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; MENTAL HEALTH; ONSET AGE; PARENT; PENSION; PRIORITY JOURNAL; QUESTIONNAIRE; SMOKING; SOCIAL PSYCHOLOGY; SWEDEN; WORK CAPACITY; WORKING TIME;

ADAPTATION, PSYCHOLOGICAL; ADULT; AGED; ALCOHOL DRINKING; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; EMPLOYMENT; FEMALE; GROWTH HORMONE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOPITUITARISM; MALE; MIDDLE AGED; SMOKING; SWEDEN;

EID: 84877065154     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2012.09.008     Document Type: Article

References (34)

1. Abs R., Mattsson A.F., Bengtsson B.Å., Feldt-Rasmussen U., Góth M.I., Koltowska-Häggström M., Monson J.P., Verhelst J., Wilton P. Isolated growth hormone (GH) deficiency in adult patients: baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. A sub-analysis of the KIMS database. Growth Horm. IGF Res. 2005, 15:349-359. on behalf of the KIMS study group.
2. Baum H., Katznelson L., Sherman J., Biller B., Hayden D., Schoenfeld D., Cannistraro K., Klibanski A. Effects of physiological growth hormone (GH) therapy on cognition and quality of life in patients with adult-onset GH deficit. J. Clin. Endocrinol. Metab. 1998, 83:3184-3189.
3. Bengtsson B.Å., Edén S., Lönn L., Kvist H., Stokland A., Lindstedt G., Bosaeus I., Tölli J., Sjöström L., Isaksson O. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J. Clin. Endocrinol. Metab. 1993, 76:309-317.
4. Burman P., Hetta J., Wide L., Månsson J.E., Ekman R., Karlsson F. Growth hormone treatment affects brain neurotransmittors and thyroxine. Clin. Endocrinol. (Oxf.) 1996, 44:319-324.
5. Burman P., Broman J., Hetta J., Wiklund I., Erfurth E.M., Hägg E., Karlsson F. Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial. J. Clin. Endocrinol. Metab. 1995, 80:3585-3590.
6. Bülow B., Hagmar L., Mikoczy Z., Nordström C.H., Erfurth E.M. Increased cerebrovascular mortality in patients with hypoptituitarism. Clin. Endocrinol. (Oxf.) 1997, 46:75-81.
7. Copinschi G., Nedeltcheva A., Leproult R., Morselli L.L., Spiegel K., Martino E., Legros J.J., Weiss R.E., Mockel J., Van Cauter E. Sleep disturbances, daytime sleepiness, and quality of life in adults with growth hormone deficiency. J. Clin. Endocrinol. Metab. 2010, 95(May (5)):2195-2202.
8. De Vile C.J., Grant D.B., Hayward R.D., Stanhope R. Growth and endocrine sequelae of craniopharyngioma. Arch. Dis. Child. 1996, 75:108-114.
9. Ehrnborg C., Hakkaart-van Roijen L., Jonsson B., Rutten F., Bengtsson B.Å., Rosén T. Cost of illness in adult patients with hypopituitarism. Pharmacoeconomics 2000, 17:621-628.
10. Ghigo E., Aimaretti G., Gianotti L., Bellone J., Arvat E., Camanni F. New approach to the diagnosis of growth hormone deficiency in adults. Eur. J. Endocrinol. 1996, 134:352-356.
11. Green D.M., Kawashima T., Stovall M., Leisenring W., Sklar C.A., Mertens A.C., Donaldson S.S., Byrne J., Robison L.L. Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. J. Clin. Oncol. 2009, 27(1 (16)):2677-2685.
12. Gurney J.G., Krull K.R., Kadan-Lottick N., Nicholson H.S., Nathan P.C., Zebrack B., Tersak J.M., Ness K.K. Social outcomes in the Childhood Cancer Survivor Study cohort. J. Clin. Oncol. 2009, 27(May (14)):2390-2395.
13. Hahner S., Loeffler M., Fassnacht M., Weismann D., Koschker A.C., Quinkler M., Decker O., Arlt W., Allolio B. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on cross-sectional analysis. J. Clin. Endocrinol. Metab. 2007, 92(October (10)):3912-3922.
14. Hakkaart-van Roijen L., Beckers A., Stevenaert A., Rutten F. The burden of illness of hypopituitary adults with growth hormone deficiency. Pharmacoeconomics 1998, 14:395-403.
15. Hernberg-Ståhl E., Luger A., Abs R., Bengtsson B.Å., Feldt-Rasmussen U., Wilton P., Westberg B., Monson J. Healthcare consumption decreases in parallell with improvements in quality of life during GH replacement in hypopituitary adults with GH deficiency. J. Clin. Endocrinol. Metab. 2001, 86:5277-5281.
16. Ho K.K., 2007.GH Deficiency Consensus Workshop Participants Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur. J. Endocrinol. 2007, 157(December (6)):695-700.
17. Holmer H., Svensson J., Rylander L., Johannsson G., Rosén T., Bengtsson B.A., Thorén M., Höybye C., Degerblad M., Bramnert M., Hägg E., Engström B.E., Ekman B., Thorngren K.G., Hagmar L., Erfurth E.M. Fracture incidence in GH-deficient patients on complete hormone replacement including GH. J. Bone Miner. Res. 2007, 22:1842-1850.
18. Howlett T.A. An assessment of optimal hydrocortisone replacement therapy. Clin. Endocrinol. (Oxf.) 1997, 46:263-268.
19. Johansson J.O., Larson G., Andersson M., Elmgren A., Hynsjö L., Lindahl A., Lundberg P.A., Isaksson O., Lindstedt S., Bengtsson B.Å. Treatment of growth hormone-deficient adults with recombinant human growth hormone increases the concentration of growth hormone in the cerebrospinal fluid and affects neurotransmittors. Neuroendocrinology 1995, 61:57-66.
20. Karavitaki N., Cudlip S., Adams C.B., Wass J.A. Craniopharyngiomas. Endocr. Rev. 2006, 27:371-397.
21. Kirchhoff A.C., Leisenring W., Krull K.R., Ness K.K., Friedman D.L., Armstrong G.T., Stovall M., Park E.R., Oeffinger K.C., Hudson M.M., Robison L.L., Wickizer T. Unemployment among adult survivors of childhood cancer: a report from the childhood cancer survivor study. Med. Care 2010, 48(November (11)):1015-1025.
22. McGauley G. Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. Acta Paediatr. Scand. 1989, 356(Suppl.):70-72.
23. Mukherjee A., Helbert M., Davis J., Shalet S. Immune function in hypopituitarism; time to reconsider?. Clin. Endocrinol. (Oxf.) 2009, (December (18)):425-431.
24. Regal M., Páramo C., Sierra J.M., García-Mayor R.V. Prevalence and incidence of hypopituitarism in an adult Caucasian population of north-western Spain. Clin. Endocrinol. (Oxf.) 2001, 55:735-740.
25. Rosén T., Edén S., Larson G., Wilhelmsen L., Bengtsson B.A. Cardiovascular risk factors in adult patients with growth. Acta Endocrinol. (Copen.) 1993, 129(September (3)):195-200.
26. Rosén T., Wirén L., Wilhelmsen L., Wiklund I., Bengtsson B.Å. Decreased psychological well-being in adult patients with growth hormone deficiency. Clin. Endocrinol. (Oxf.) 1994, 40:111-116.
27. Rosilio M., Blum W., Edwards D., Shavrikova E., Valle D., Lamberts S., Erfurth E.M., Webb S., Ross R., Chihara K., Henrich G., Herschbach P., Attanasio A. Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). J. Clin. Endocrinol. Metab. 2004, 89:1684-1693.
28. Saller B., Mattsson A., Kann P., Koppeschaar H., Svensson J., Pompen M., Koltowska-Häggström M. Healthcare utilization, quality of life and patient-reported outcomes during two years of GH replacement therapy in GH-deficient adults - comparison between Sweden, The Netherlands and Germany. Eur. J. Endocrinol. 2006, 154:843-850.
29. Svensson J., Mattsson A., Rosén T., Wirén L., Johannsson G., Bengtsson B.Å., Koltowska-Häggström M. Three-years of GH replacement therapy in GH-deficient adults: effects on quality of life, patient-reported outcomes and healthcare consumption. Growth Horm. IGF Res. 2004, 14:207-215.
30. Tomlinson J.W., Holden N., Hills R.K., Wheatley K., Clayton R.N., Bates A.S., Sheppard M.C., Stewart P. Association between premature mortality and hypopituitarism. Lancet 2001, 357:425-431.
31. Toogood A.A., Beardwell C.G., Shalet S.M. The severity of growth hormone deficiency in adults with pituitary disease is related to the degree of hypopituitarism. Clin. Endocrinol. (Oxf.) 1994, 41:511-516.
32. van der Klaauw A.A., Kars M., Biermasz N.R., Roelfsema F., Dekkers O.M., Corssmit E.P., van Aken M.O., Havekes B., Pereira A.M., Pijl H., Smit J.W., Romijn J.A. Disease-specific impairments in quality of life during long-term follow-up of patients with different pituitary adenomas. Clin. Endocrinol. (Oxf.) 2008, 69(5):775-784.
33. Wirén L., Bengtsson B.A., Johannsson G. Beneficial effects of long-term GH replacement therapy on quality of life in adults with GH deficiency. Clin. Endocrinol. (Oxf.) 1998, 48:613-620.
34. Woodhouse L., Mukherjee A., Shalet S., Ezzat S. The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults. Endocr. Rev. 2006, 27:287-317.